NICE backs Rinvoq for moderate active RA
Decision expands access to oral therapy to around 27,000 people in England
Read More
Tag: rheumatoid arthritis
NICE broadens access to treatments for rheumatoid arthritis
New guidance enables earlier access to certain treatments, including biologics
Read More
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
Over 400,000 people in the UK live with RA
Read More
NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis
Around 400,000 people in the UK are living with rheumatoid arthritis
Read More
Gilead’s oral JAK inhibitor filgotinib wins EU approval
Treatment is indicated for use in adults with moderate-to-severe active rheumatoid arthritis
Read More
Rinvoq NICE approval could benefit 54,000 people
Rinvoq has already been available in the US since last August, and in Europe since December.
Read More
Positive late stage rheumatoid arthritis trial results for Abbvie
Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.
Read More
EU green light for new Humira biosimilar
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
Read More
Gilead, Galapagos’ filgotinib hits goals in RA trial
Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.
Read More
Celltrion calls for wider use of biologics in RA
Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to such treatment.
Read More
US approves Lilly/Incyte’s Olumiant
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Read More
FDA advisors back Lilly/Incyte’s rheumatoid arthritis drug
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
